



Iran University of Medical Sciences
and Health Services

In the name of Allah

Parvaneh Rahimi-Moghaddam M.D., Ph.D.



Department of Pharmacology
College of Medicine
Iran University of Medical Sciences
Tehran, Iran

TEL: 021 86703139

FAX: 021 88622696

MOBILE: 0912 6029498

E-Mail: rahimi.p@iums.ac.ir

Date of Birth:	July 23, 1967
Place of Birth:	Tehran (Iran)
Gender:	Female
Marital Status:	Married, Two children

EDUCATION

Spring 2002

Ph.D. (Pharmacology)

University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

Courses Completed

Pharmacology, Biochemical Techniques, Neuropharmacology,
Cardiovascular-Renal Pharmacology, Statistical Methods, Special Topics in
Pharmacology (receptor binding assay)

Overall Average: 86.5%

Fall 1993

M.D. (Doctor of Medicine)

Islamic Azad University, Tehran, Iran.

Overall Average: 83.25%

PUBLICATIONS

in the peer-reviewed journals

1. Jurado A, **Rahimi-Moghaddam P**, Bar-Jurado S, Richardson JS, Jurado M, Shuaib A (1999) Genetic markers on HIV-1 gp120 C2-V3 region associated with expression or absence of cognitive motor complex in HIV/AIDS. *Journal of NeuroAIDS* 2 (2): 15-28.
2. **Rahimi-Moghaddam P**, Upadrashta Y, and Weil JA (2003) EPR of manganese-containing plasticine: spectral simulation and use as an internal standard for comparison of the signal intensities of various free-radical EPR spectra. *Applied Magnetic Resonance* 24: 113-125.
3. Amarowicz R, Pegg RB, **Rahimi-Moghaddam P**, Barl B, Weil JA (2004) Free-radical-scavenging capacity and antioxidant activity of selected plant species from the Canadian prairies. *Food Chemistry* 84: 551-562.
4. Eftekhar Z, **Rahimi-Moghaddam P**, Dehdar-Dargahi F, Yarandi F (2004) Single-agent therapy for low risk gestational trophoblastic neoplasia (LRGTN): a preliminary report on a randomized clinical trial to compare pulse-methotrexate versus pulse-dactinomycin. *Iranian Journal of Pharmacology and Therapeutics* 3: 41-44.
5. Eftekhar Z, **Rahimi-Moghaddam P**, Izadi-Mood N, Yarandi F (2005) Non-Puerperal uterine inversion caused by uterine sarcoma: a case report. *Australian and New Zealand Journal of Obstetrics and Gynecology* 45(1): 82-83.
6. Eftekhar Z, Izadi-Mood N, Yarand F, Khodamoradi M, **Rahimi-Moghaddam P** (2005) Can we substitute brush cytology for biopsy in the evaluation of cervical lesions under the guidance of colposcopy? *International Journal of Gynecological Oncology* 15: 489-492.
7. Eftekhar Z, **Rahimi-Moghaddam P**, Yarandi F, Brojerdi R (2005) Accuracy of visual inspection with acetic acid (VIA) for early detection of cervical dysplasia in Tehran, Iran. *Asian Pacific Journal of Cancer Prevention* 6: 69-71.
8. **Rahimi-Moghaddam P**, Yarandi F, Tahmasbi M (2005) An ovarian torsion in severe spontaneous ovarian hyperstimulation syndrome associated with a singleton pregnancy. *Journal of Obstetrics and Gynaecology* 25: 393-394.
9. Izadi-Mood N, Eftekhar Z, Haratian A, Saeedi L, **Rahimi-Moghaddam P**, Yarandi F (2006) A cytohistologic study of atypical glandular cells detected in cervical smears during cervical screening tests in Iran. *International Journal of Gynecological Cancer*. 16: 257-261.
10. Eftekhar Z, Yarandi F, Izadi-Mood N, **Rahimi-Moghaddam P** (2006) Malignant mixed Mullerian tumor of the uterus associated with tamoxifen therapy in a patient with a history of breast cancer. *Iranain Journal of Pharmacology and Therapeutics* 5: 81-82.

11. Sepahvand F, **Rahimi-Moghaddam P**, Shafiei M, Ghaffari SM, Rostam-shirazi M, Mahmoudian M (2007) Frequency of paraoxonase (PON1) 192 and 55 polymorphism and its effect on serum PON1 activity in a healthy Iranian population. *Journal of Toxicology and Environmental health (Part A)* **70**: 1125–1129.
12. Sepahvand F, Shafiei M, Ghaffari SM, **Rahimi-Moghaddam P**, Mahmoudian M (2007) Paraoxonase phenotype distribution in a healthy Iranian population. *Basic & Clinical Pharmacology & Toxicology* **101**: 104–107.
13. Heidari N, Goliaei B, **Rahimi-Moghaddam P**, Rahbar-Roshandel N, Mahmoudian M (2007) Apoptotic pathway induced by noscapine in human myelogenous leukemic cells. *Anticancer Drugs*. **18**: 1139-1147.
14. **Rahimi-Moghaddam P**, Zahedi M, Eftekhari Z (2007) Comparison of metronidazole and ceftizoxime in prophylaxis of post-hysterectomy infections. *Iranian Journal of Pharmacology and Therapeutics* **6**: 155-157.
15. Mahmoudian M, **Rahimi-Moghaddam P** (2008) The life and work of Abu ul-Ala Shirazi (d. 1001): a Persian pioneer in the treatment of malaria, in the style of Rhazes (865–925). *Journal of Medical Biography* **16**: 186–187.
16. Mahmoudian M, **Rahimi-Moghaddam P** (2009) The anti-cancer activity of noscapine: a review. *Recent Patents on Anti-Cancer Drug Discovery* **4**: 92-97.
17. Tavakoli-Far B, Rahbar-Roshandel N, **Rahimi-Moghaddam P**, Mahmoudian M (2009) Neuroprotective effects of mebudipine and dibudipine on cerebral oxygen–glucose deprivation/reperfusion injury. *European Journal of Pharmacology* **610**:12–17.
18. Benaissa F, Mohseni-Rad H, **Rahimi-Moghaddam P**, Mahmoudian M (2009) Berberine reduces the hypoxic-ischemic insult in rat pup brain. *Acta Physiologica Hungarica* **96**: 213–220.
19. Elmi M, **Rahimi-Moghaddam P**, Abdi K, Shafiee-Ardestani M, Mahmoudian Massoud (2009) Ciprofloxacin: a novel therapeutic agent for iron overload? *Turkish Journal of Hematology* **26**: 114-117.
20. Izadi-Mood N, Samadi N, **Rahimi-Moghaddam P**, Sarmadi S, Eftekhari Z, Yarandi F (2009) Pure ovarian choriocarcinoma: report of two cases. *Journal of Research in Medical Sciences* **14**(5): 327-330.
21. Namvaran F, **Rahimi-Moghaddam P**, Azarpira N (2011) Genotyping of peroxisome proliferator-activated receptor gamma (PPAR- γ) polymorphism (Pro12Ala) in Iranian population. *Journal of Research in Medical Sciences* **16**(3):291-296.
22. Namvaran F, Azarpira N, **Rahimi-Moghaddam P**, Dabbaghmanesh MH (2011) Polymorphism of peroxisome proliferator-activated receptor γ (PPAR γ) Pro12Ala in the Iranian population: relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes. *European Journal of Pharmacology* **671**(1-3):1-6.
23. Namvaran F, Azarpira N, Geramizadeh B, **Rahimi-Moghaddam P** (2011) Distribution and genotype frequency of adiponectin (+45 T/G) and adiponectin receptor2 (+795 G/A) single nucleotide polymorphisms in Iranian population. *Gene* **486**(1-2):97-103.

24. **Rahimi-Moghaddam P**, Ebrahimi SA, Ourmazdi H, Selseleh M, Karjalian M, Haj -Hassani G, Alimohammadian MH, Mahmoudian M, Shafiei M (2011) In vitro and in vivo activities of Peganum harmala extract against Leishmania major. *Journal of Research in Medical Sciences* **16**(8):1032-1039.
25. Namvaran F, **Rahimi-Moghaddam P**, Azarpira N, Nikeghbalian S (2012) The association between adiponectin (+45T/G) and adiponectin receptor -2 (+795G/A) single nucleotide polymorphisms with cirrhosis in Iranian population. *Molecular Biology Reports* **39**(3):3219-3223.
26. Namvaran F, **Rahimi-Moghaddam P**, Azarpira N, Dabbaghmanesh MH (2012) Polymorphism of adiponectin (45T/G) and adiponectin receptor -2 (795G/A) in an Iranian population: relation with insulin resistance and response to treatment with pioglitazone in patients with type 2 diabetes mellitus. *Molecular Biology Reports* **39**(5):5511-5518.
27. Aryamanesh S, Ebrahimi SM, Abotaleb N, Nobakht M, **Rahimi-Moghaddam P** (2012) Role of endogenous vitamin E in renal ischemic preconditioning process: differences between male and female rats. *Iranian Biomedical Journal* **16**(1):44-51.
28. Kiani Z, Shafiei M, **Rahimi-Moghaddam P**, Karkhane AA, Ebrahimi SA (2012) In vitro selection and characterization of deoxyribonucleic acid aptamers for digoxin. *Analytica Chimica Acta* **748**: 67–72.
29. Namvaran F, **Rahimi-Moghaddam P**, Azarpira N, Dabbaghmanesh MH, Bakhshayeshkaram M, Namvaran MM (2013) Changes in bone biological markers after treatment of Iranian diabetic patients with pioglitazone: No relation to polymorphism of PPAR- γ (Pro12Ala). *Journal of Research in Medical Sciences* **18**(4):277-282.
30. Shojaei ES, Falahati M, Zaini F, Kord Bache P, **Rahimi-Moghaddam P**, Aghamirian MR, Makhdoomi A, Ameri S (2014) A Effects of several common antifungal drugs (clotrimazole, miconazole, fluconazole) alone and in combination with amphotericin B on candida species isolated from chronic candidal vulvovaginitis. *Journal of Fasa University of Medical Sciences* **4**(3):327-334. (in Farsi)
31. Emzhik M, **Rahim-Moghaddam P**, Ebrahimi SA, Keyhanfar F, Moazzam A (2015) Commentary on prevention a possible drug–drug interaction: is concurrent administration of orlistat and pioglitazone hncrase the risk of durg-induced hepatotoxicity. *International Journal of Preventive Medicine*; **6**:16-19.
32. **Rahimi-Moghaddam P**, Hashemi-Setobadi H, Ghazinejhadian- Shoostari F (2015) Effect of Allicin on Tamoxifen-sensitive MCF-7 Breast Cancer Cells. *Journal of Medicinal Plants*; **14**: 101-111. (in Farsi)
33. Ameri S, Falahati M, Kordbache P, Zaini F, **Rahimi-Moghaddam P**, Farahyar S, Shojaei ES, Afshar-Moghaddam S (2015) Activities of fluconazole in combination with terbinafine against non-albicans Candida species isolated from the patients with recurrent vulvovaginal candidiasis in comparison with ciclopirox olamine. *Hormozgan Medical Journal* **18**(6):515-522.
34. Ahmadi P, Hoseini R, **Rahimi-Moghaddam P**, Ahmadi SAY (2016) Sensitivity or resistance to steroid therapy in children with idiopathic nephrotic syndrome is not associated with polymorphism

- of angiotensin converting enzyme (ACE). *Journal of Applied Pharmaceutical Science* **6**(12):206-208.
35. Fotovat-Eskandari N, Vahabzadeh G, Golab F, Karimzadeh F, **Rahimi-Moghaddam P**, Nasiripour S, Shabani R (2016) Neuroprotective Effects of Stiripentol on Oxygen-Glucose Deprivation in Primary Culture of Fetal Mice Cortical Neurons. *Shafaye Khatam* **5**:10-17. (in Farsi)
36. Ahmadi P, Ahmadvand H, Ahmadi SAY, Hoseini R, **Rahimi-Moghaddam P** (2017) A Narrative review on nephrotic syndrome emphasizing its correlation with polymorphism of angiotensin converting enzyme and renin-angiotensin system. *Crescent Journal of Medical and Biological Sciences* **4**(2):41–46.
37. Amirkalali B, Sohrabi MR, **Rahimi-Moghaddam P**, Gholami A, Hosseinzadeh P, Keyvani H, Shidfar F, Zamani F (2017) The Association of nicotinamide phosphoribosyltransferase polymorphism with markers of hepatic Injury and de novo lipogenesis in nonalcoholic fatty liver disease. *Hepatitis Monthly* **17**(6):e13570.
38. Majdabadi N, Falahati M, Heidarie-Kohan F, Farahyar s, **Rahimi-Moghaddam P**, Ashrafi-Khozani M (2018) Study on synergistic effect of 2-phenylethanol and clotrimazole on candida species isolated from patients with chronic vulvovaginal candidiasis. *Tehran University Medical Journal* **75**(11): 839-847.
39. Majdabadi N, Falahati M, Heidarie-Kohan F, Farahyar s, **Rahimi-Moghaddam P**, Ashrafi-Khozani M, Razavi T, Mohammadnejad S (2018) Effect of 2-phenylethanol as antifungal agent and common antifungals (amphotericin B, fluconazole, and itraconazole) on candida species isolated from chronic and recurrent cases of candidal vulvovaginitis. *Assay and Drug Development Technologies* **16**(3): 141-149.
40. Asgharpour Sarouey L, Khanaliha K, **Rahimi-Moghaddam P**, Tabatabaie F (2018) Evaluating the effect of cinnarizine on promastigotes and amastigotes forms of *Leishmania major* . *Infectious Disorders-Drug Targets* **18**, 1-8.
41. Asgharpour Sarouey L, Khanaliha Kh, **Rahimi-Moghaddam P**, Khorrami S, Dayer MS, Tabatabaie F (2019) In Vitro Effects of Ketotifen and Cromolyn Sodium on Promastigotes and Amastigotes of *Leishmania major*. *Jundishapur Journal of Microbiology* **12**(1):e82389.
42. Alinaghian N, Abdollahi E, Torab M, Khodaparast M, Zamani F, **Rahimi-Moghaddam P** (2019) Gender-related relation between metabolic syndrome and S447X and HindIII polymorphisms of lipoprotein lipase gene in northern Iran. *Gene* **706**:13-18.
43. Ghazizadeh F, Shafiei M, Falak REbrahimi SA, **Rahimi-Moghaddam P** (2020) Xanthomicrol Exerts Antiangiogenic and Antitumor Effects in a Mouse Melanoma (B16F10) Allograft Model. *Evidence-based Complementary and Alternative Medicine* 8543872.
44. Ghorbani E, Mohammadi M, Malakouti SK, Mohammadi-Kangarani H, Abdollahi E, Torab M, **Rahimi-Moghaddam P** (2021) Association of ACE Gene Insertion/Deletion Polymorphism with Suicidal Attempt in an Iranian Population. *Biochemical Genetics* **59**:31–41.

45. Namazi MJ, Nikpour S, **Rahimi-Moghaddam P**, Golmohammadi R, Tabatabaie F (2021) Evaluation of glutathione bioactivity on toxoplasma gondii in balb/c mice post impact of selenium and calcium supplementation . *Infectious Disorders - Drug Targets* 21:452–458.
46. Torab M, Jafari-Sabet M, Najafizadeh P, Sadegipour AR, **Rahimi-Moghaddam P**, Ebrahimi SA. (2022) Oral administration of phenylalanine molecularly imprinted polymer (MIP) benefits PKU mouse model. *Journal of Inherited Metabolic Diseases*: 1–14.

in the conference proceedings

1. **Rahimi-Moghaddam P**, Jurado A, Jurado M, Bar-Jurado S, Shuaib A, Richardson JS (1996) Sequence Homologies Between Beta Amyloid Proteins and HIV-1 gp120 V3 Region with and without Cognitive Motor Complex (CMC). *XI International Conference on AIDS*, Abstracts, **11** (2): 295 (abstract no. Th.B.4255), Vancouver, Canada.
2. Jurado A, **Rahimi-Moghaddam P**, Bar-Jurado S, Jurado M (1996) Markers Associated with Demential and Non-Demential Patterns in Sequences of the gp120 V3 Region of HIV-1. *XI International Conference on AIDS*, Abstracts, **11** (1): 274 (abstract no. Tu.A.2055), Vancouver, Canada.
3. **Rahimi-Moghaddam P**, Jurado A, Bar-Jurado S, Shuaib A, Richardson JS (1996) A comparison between HIV-1 gp120 V3 Region Sequences Related to Patients With and Without Dementia and Beta Amyloid Protein Sequences. *First Annual Meeting of Iranian Graduate Students in North America*, Edmonton, Canada.
4. **Rahimi-Moghaddam P**, Bar-Jurado S, Richardson JS, Jurado A (1997) Homology between HIV-1 gp120 V3 region from AIDS patients with cognitive motor complex and neurotoxic beta amyloid protein. 6th Annual Canadian Conference on HIV/AIDS Research, *The Canadian Journal of Infectious Diseases*, **8** Suppl. A: 69A.
5. Jurado A, **Rahimi-Moghaddam P**, Bar-Jurado S, Jurado M (1997) Computerized analysis of sequences of HIV-1 gp120 V3 region reveals markers specific for the presence as well as for the absence of cognitive motor complex. 6th Annual Canadian Conference on HIV/AIDS Research, *The Canadian Journal of Infectious Diseases*, **8** Suppl. A: 69A.
6. Morrell T, Bar-Jurado S, **Rahimi-Moghaddam P**, Jurado A (1997) Phylogenetic analysis of the neurotoxic motif shared by beta amyloid protein and HIV-1 gp120 V3 loop sequences associated with cognitive motor complex. 6th Annual Canadian Conference on HIV/AIDS Research, *The Canadian Journal of Infectious Diseases*, **8** Suppl. A: p. 68A.
7. Richardson JS, **Rahimi-Moghaddam P**, Bar-Jurado S, Shuaib A, Jurado A (1998) The neurotoxic fragment of β -amyloid is found in the gp120 coat protein of strains of dementia-causing HIV, *Journal of Neurochemistry*, **70**: S27.
8. **Rahimi-Moghaddam P**, Bar-Jurado S, Jurado A, Richardson JS (1998) An amino acid motif common to beta amyloid protein and to neurodegenerative viruses may trigger neuronal destruction. *The FASEB*

Journal, **12**: A752.

9. Jurado A, **Rahimi-Moghaddam P**, Bar-Jurado S, Richardson JS, Jurado M, Shuaib A (1998) Markers associated with clinical expression of cognitive motor complex in patients with HIV/AIDS in the gp120 C2-V3 region. *Journal of Neurovirology*, **4**: p. 354.
10. Jurado A, Morrell T, **Rahimi-Moghaddam P**, Bar-Jurado S (1998) Molecular systematics: neurodegeneration in HIV/AIDS, Alzheimer disease and prion diseases. *Journal of Neurovirology*, **4**: p. 354.
11. **Rahimi-Moghaddam P**, Bar-Jurado S, Richardson JS, Jurado A (1998) The neurotoxicity of a pentapeptide from HIV-1 gp120 V3 and beta amyloid protein can be attenuated by antioxidant drugs. *Journal of Neurovirology*, **4**: p. 363.
12. **Rahimi-Moghaddam P**, Jurado A, Richardson JS (1998) The neurotoxicity of a 5 amino acid sequence common to beta amyloid and to HIV-1 gp120 is attenuated by antioxidants. *Naunyn-Schmiedeberg's Archives of Pharmacology*, **358** (Suppl.1): R33, Munich, Germany.
13. **Rahimi-Moghaddam P**, Bar-Jurado S, Richardson JS, Jurado A (1998) A pentapeptide from HIV-1 gp120 V3 region is reducing PC12 neuronal cell line viability. *XII International Conference on AIDS Abstracts*, **12**:1060-1 (abstract no. 60334), Geneva, Switzerland.
14. Richardson JS, **Rahimi-Moghaddam P** (1999) Proteins from 4 neurodegenerative viruses contain a 5 amino acid sequence homologous to the neurotoxic β -amyloid fragment 29-33. Evidence for a viral origin for dementia? *Neurochemistry Winter Conference*, Denver, Colorado, USA.
15. **Rahimi-Moghaddam P**, Song J, Du J-L, Richardson JS, Weil JA (1999) Free-radical formation involving the pentapeptide H₂N-GAIIG-CO₂H, residues 29-33 of beta-amyloid, the Alzheimer protein. *22nd International EPR Symposium, 41st Rocky Mountain Conference on Analytical Chemistry*, Denver, Colorado, USA.
16. **Rahimi-Moghaddam P**, Eftekhari Z, Yarandi F (2004) Single-agent therapy for low risk gestational trophoblastic tumor: A comparison between pulse-methotrexate versus pulse- actinomycin. IGCS 10th Biennial Meeting, *International Journal of Gynecological Cancer* **14** (supplement 1): 96 (Abstract no. 341), Edinburgh, Scotland.
17. Izadi-Mood N, Izadi-Mood N, **Rahimi-Moghaddam P**, Tabatabaee M (2004) Assessment of hydatidiform mole based on pathologic and sonographic findings in Mirza Koochak Khan Hospital in Iran. *IGCS 10th Biennial Meeting, International Journal of Gynecological Cancer* **14** (supplement 1): 188 (Abstract no. 678), Edinburgh, Scotland.
18. **Rahimi-Moghaddam P** (2005) An amino acid motif common to beta amyloid protein and to neurodegenerative viruses may trigger neuronal destruction. 20th International Congress of Pathology, *Virchow Archives of Pathology*, Volume 247(2): 546.
19. Rahimi-Moghaddam P (2005) Role of free radicals in Pathogenesis of pentapeptide Glycine-Alanine-Isoleucine-Isoleucine-Glycine. 17th Iranian Congress of Physiology and Pharmacology, October 1-4, Kerman, Iran.
20. Rahimi-Moghaddam P, Eftekhari Z (2006) Comparison of metronidazole and ceftizoxim in prophylaxis of post-hysterectomy infections. 15th World Congress of Pharmacology. *Acta Pharmacologica Sinica*,

Supplement 1: 55.

21. **Rahimi-Moghaddam P, Eftekhari Z (2007)** Study of Megestrol acetate in treatment of differentiated adenocarcinoma of endometrium stage Ia. 18th Iranian Congress of Physiology and Pharmacology, August 10-13, Mashad, Iran.
- Rahimi-Moghaddam P, Eftekhari Z (2006)** Comparison of metronidazole and ceftizoxim in prophylaxis of post-hysterectomy infections. 15th World Congress of Pharmacology. *Acta Pharmacologica Sinica*, Supplement 1: 55.
22. **Rahimi-Moghaddam P, Karjalainen M., Mahmoudian M (2007)** In vitro antiproliferative effects of *Peganum harmala* seeds extract. 3RD International Congress on Traditional Medicine and Materia Medica, July 17-20, Kuala Lumpur, Malaysia.
23. **Rahimi-Moghaddam P, Eftekhari Z (2008)** Assessment of the efficacy of megestrol in treatment of patients with stage IA well-differentiated endometrial adenocarcinoma. *The 12th International Gynecologic Cancer Society Meeting*, October 25-28, Bangkok, Thailand.
24. **Namvaran F, P Rahimi-Moghaddam, N Azarpira (2010)** Distribution and genotype frequency of the SNP to diabetes and response to pioglitazone. 16th World Congress on Basic and Clinical Pharmacology (WorldPharma2010), July 17-23, Copenhagen, Denmark, Basic & Clinical Pharmacology & Toxicology, 107 (Suppl. 1): 485.
25. **Rahimi-Moghaddam P (2010)** Effects of genetic polymorphisms of angiotensin converting enzyme in Iranian children with idiopathic nephrotic syndrome. 16th World Congress on Basic and Clinical Pharmacology (WorldPharma2010), July 17-23, Copenhagen, Denmark, Basic & Clinical Pharmacology & Toxicology, 107 (Suppl. 1): 535.
26. **Rahimi-Moghaddam P, Namvaran F, Azarpira N, Dabbaghmanesh MH (2011)** Polymorphism of PPAR γ in an Iranian population: relation with osteoporosis after treatment with pioglitazone in diabetes type 2. First Middle-East & Africa Osteoporosis Meeting, October 19-22, Dubai, UAE, Osteoporosis International 22 (Suppl 5):S727.
27. **Rahimi-Moghaddam P, Moazzam Ashraf-Sadat, Rasouli Homa (2012)** Neuroprotective effect of senna extract in rat model of Parkinson's disease. 6th European Congress of Pharmacology, July 17-20, Granada, Spain.
28. **Rahimi-Moghaddam P, Namvaran F, Azarpira N, Dabbaghmanesh M (2013)**. Changes in bone biological markers after treatment of Iranian diabetic patients with pioglitazone: No relation to polymorphism of PPAR γ (Pro12Ala). 21st Iranian Congress of Physiology and Pharmacology, August 23-27, Tabriz, Iran.
29. **Rahimi-Moghaddam P, Emzhi M (2015)** Prevention a Possible Drug-Drug Interaction: Is Concurrent Administration of Orlistat and Pioglitazone Increase the Risk of Drug-Induced Hepatotoxicity? 29th World Congress on Heart Diseases, July 25-27, Vancouver, BC, Canada.

Theses and reports:

1. **Rahimi-Moghaddam P. (1993)**, Study of hyperthyroid cases in women with mole hydati-form, Islamic Azad University, Tehran, Iran.

2. **Rahimi-Moghaddam P. (1997)**, Tutorial manual for computer applications in biology, International Summer School of HIV/AIDS, University of Saskatchewan.
 3. **Rahimi-Moghaddam P. (2002)**, Role of free radicals in neurodegenerative diseases, Ph.D. Thesis, College of Graduate Studies and Research, University of Saskatchewan, Canada.
-

AWARDS

1. College of Graduate Studies and Research Scholarship, University of Saskatchewan, M.Sc. program (September 1, 1995- August 30,1996).
2. College of Graduate Studies and Research Scholarship, University of Saskatchewan, Ph.D. program (September 1, 1996- August 30, 1999).
3. Scholarship award of the XI International Conference on AIDS, Vancouver, Canada, July 1996.
4. Travel award from the University of Saskatchewan to attend the National Conference on AIDS, May 1997, Ottawa, Ontario, Canada.
5. Travel award from the University of Saskatchewan to attend the FASEB Conference, May 1998, San Francisco, CA, USA.
6. Travel award from the College of Medicine, University of Saskatchewan to attend the FASEB Conference, May 1998, San Francisco, CA, USA.
7. Travel award from Upjohn Pharmaceutical Company to attend the XIII International Conference of Pharmacology, July 1998, Munich, Germany.
8. Travel award from the Pharmacological Society of Canada (PSC) to attend the XIII International Conference of Pharmacology, July 1998, Munich, Germany.
9. Arthur Smyth Scholarship from the College of Medicine, University of Saskatchewan for last year of Ph.D. program (September 1, 2000- January 30, 2001).
10. Best Academic Half-Day Award (First prize), Internal Medicine Residents Academic
11. Half-Day 2001-2002, College of Medicine, University of Saskatchewan, Canada.
12. Best Journal Referee Award, Research Day, Chancellor for Research & Technology, Iran University of Medical Sciences, November 2008, Tehran, Iran.
13. Best Advisor for Medical Students, College of Medicine, University of Medical Sciences, April 2009, Tehran, Iran.

TEACHING EXPERIENCE

1. Tutorial leader for Pharmacology course for undergraduate pharmacy students (Fall and Winter 1996-97, 1999-2000, and 2000-2001, Department of Pharmacology, University of Saskatchewan, Canada).
2. Teaching Pharmacology course for undergraduate medical, nursing, midwifery and family health Student, 2004-present, Department of Pharmacology, Iran University of Medical Sciences, and Tehran University of Medical Sciences, Tehran, Iran.

3. Teaching advanced pharmacology for Ph.D. students. 2005-present, Department of Pharmacology, Iran University of Medical Sciences, and Tehran University of Medical Sciences, Tehran, Iran.

WORK EXPERIENCE

1. Graduate research assistant, Department of Applied Microbiology and Food Sciences, University of Saskatchewan, Canada (1999-2002).
2. Assistant Professor, Department of Pharmacology, Iran University of Medical Sciences, Tehran, Iran, 2004-2014.
3. Associate Professor, Department of Pharmacology, Iran University of Medical Sciences, Tehran, Iran, 2014-present.

Research Interests

1. Pharmacogenetics studies including genotype polymorphism effects on drug
2. Metabolic syndrome: mechanisms and management

ردیف	عنوان پایان نامه	مقطع تحصیلی			سمت
		Ph.D.	دکتری حرفه ای	کارشناسی ارشد	
۷	بررسی فعالیت ضد قارچی تربینافین و فلوکونازول به تنهایی و در همبست با یکدیگر و مقایسه آنها با اثر سیکلوپیروکس اولامین بر روی گونه های کاندیدای غیر آلبیکانس جدا شده از بیماران مبتلا به ولووژینیت عود کننده کاندیدایی به روش میکودیلوشن در محیط مایع (سختاوت عامری سیاهویی)			قارچ شناسی	استاد مشاور دکتر مهربان فلاحتی دکتر فریده زینی دکتر پریوش کردبچه دکتر پروانه رحیمی مقدم
۸	بررسی تأثیر ارلیستات بر سمیت ناشی از پیوگلیتازون در رده سلولی HepG2 (مرجان عمژیک)			سم شناسی	استاد راهنما دکتر پروانه رحیمی مقدم دکتر سلطان احمد ابراهیمی دکتر فریبرز کیهانفر
۹	بررسی اثر محافظ نورونی کمپفرول در مرگ سلولی حاصل از فقدان اکسیژن و گلوکز در کشت سلولی PC12 (سارا رشادت)		پزشکی		استاد راهنما دکتر پروانه رحیمی مقدم
۱۰	بررسی اثر محافظ نورونی گل ساعتی در مدل کشت سلولس بیماری پارکینسون (مهديه میری)		پزشکی		استاد راهنما دکتر پروانه رحیمی مقدم
۱۱	بررسی اثر محافظ نورونی نوسکاپین در مرگ سلولی حاصل از فقدان اکسیژن و گلوکز در کشت سلولی PC12 (بهاره عسکری)		پزشکی		استاد راهنما دکتر پروانه رحیمی مقدم
۱۲	بررسی اثر محافظ نورونی کمپفرول در مدل کشت سلولس بیماری پارکینسون (نسرین امینی کردکندی)		پزشکی		استاد راهنما دکتر پروانه رحیمی مقدم

ردیف	عنوان پایان نامه	مقطع تحصیلی			سمت
		کارشناسی ارشد	دکتری حرفه ای	Ph.D.	
۱۳	بررسی اثر ضد تشنجی جزء سافرانال عصاره زعفران در موش های صحرایی نر تحت کیندلینگ الکتریکی آمیگدال (فاطمه صابری)		پزشکی		استاد راهنما
۱۴	بررسی اثر محافظ نورونی عصاره هیدروالکلی گیاه سنا در مرگ سلولی حاصل از فقدان اکسیژن و گلوکز در کشت سلولی PC12 (زهرا غلامعلی زاده)		پزشکی		استاد راهنما
۱۵	بررسی ارتباط پلی مرفیسم ژن گیرنده ۱ آنژیوتانسین و پاسخ به درمان با کورتیکواستروئیدها در کودکان ایرانی مبتلا به سندرم نفروتیک (مهدی چینی چیان)		پزشکی		استاد راهنما
۱۶	بررسی ارتباط پلی مرفیسم ژن آنزیم تبدیل کننده آنژیوتانسین و پاسخ به درمان با کورتیکواستروئیدها در کودکان ایرانی مبتلا به سندرم نفروتیک (پری السادات احمدی)		پزشکی		استاد راهنما
۱۷	بررسی اثر محافظتی نوسکاپین بر مرگ سلولی حاصل از فقدان اکسیژن و گلوکز و رپرفیوژن در کشت سلول های H9C2 (حمیدرضا سلطانی)		پزشکی		استاد راهنما
۱۸	بررسی مقایسه ای اثر محافظتی کمپفول و بربرین بر مرگ سلول های قلبی در اثر فقدان اکسیژن و گلوکز در کشت سلولی H9C2 (محمد ابوحسینی طبری)		پزشکی		استاد راهنما

ردیف	عنوان پایان نامه	مقطع تحصیلی			محل انجام	اسامی همکاران	سمت
		کارشناسی ارشد	دکتری حرفه ای	Ph.D.			
۱۹	بررسی شیوع پلی مورفیسم ۴۶۸۹G/T- در ژن ویسفاتین و ارتباط آن با اختلال در عملکرد بافت چربی، ترکیب اسیدهای چرب غشاء گلبول های قرمز و میزان التهاب و فیبروز کبدی در بیماران مبتلا به کبد چرب غیر الکلی (بهاره امیرکلالی)			پژوهشی علوم بالینی	بیمارستان فیروزگر	دکتر فرهاد زمانی دکتر فرزاد شیدفر دکتر محمود جلالی دکتر پروانه رحیمی مقدم دکتر علی غلامی	استاد مشاور
۲۰	بررسی اثرات ضد توموری زانتومیکرول در سلول های ملانوما B16F10 در کشت سلولی (in vitro) و در موش c57 توموردار (in vivo) (فواد قاضی زاده)			فارماکولوژی	گروه فارماکولوژی	دکتر پروانه رحیمی مقدم دکتر معصومه شفیعی دکتر ناصر درخشانی دکتر محسن رضوی	استاد راهنما
۲۱	بررسی اثر داروهای کتوتیفن، کرومولین سدیم و سیناریزین بر پروماستیگوت و آماستیگوت لیشمانیا ماژور در شرایط آزمایشگاهی (لیما اصغرپور سارویی)	انگل شناسی			گروه انگل شناسی	دکتر فاطمه طباطبایی دکتر پروانه رحیمی مقدم	استاد مشاور
۲۲	بررسی ارتباط پلی مورفیسم ژن آنزیم تبدیل کننده آنژیوتانسین و اقدام به خودکشی در جامعه ایرانی (مهسا محمدی)		داروسازی		گروه فارماکولوژی	دکتر پروانه رحیمی مقدم دکتر سیدکاظم ملکوتی دکتر سیده زهرا موسوی دکتر حامد محمدی کنگرانی	استاد راهنما
۲۳	بررسی پلی مورفیسم ۴۶۸۹G/T ژن ویسفاتین در جمعیت چاق ایرانی (سپیده افشاری معز)	سم شناسی			گروه فارماکولوژی	دکتر پروانه رحیمی مقدم دکتر پروانه نجفی زاده	استاد راهنما
۲۴	بررسی اثر محافظ نورونی داکسی سیکلین در مدل کشت سلولی بیماری پارکینسون (مهشاد اسماعیلی)		پزشکی		گروه فارماکولوژی	دکتر پروانه رحیمی مقدم	استاد راهنما

استاد راهنما	دکتر پروانه رحیمی مقدم دکتر فرهاد زمانی	گروه فارماکولوژی		پزشکی		بررسی پلی مورفیسزم پرولین/۱۲/آلانیل گیرنده های فعال کننده پراکسیزوم گاما (PPAR γ) در جمعیت چاق در شهر آمل (شیمای قرهی جواهریان)	۲۵
استاد مشاور	دکتر سلطان احمد ابراهیمی دکتر مجید جعفری ثابت دکتر علیرضا صادقی پور دکتر پروانه رحیمی مقدم دکتر پروانه نجفی زاده	گروه فارماکولوژی	فارماکولوژی			بررسی تاثیر تجویز خوراکی پلیمر دارویی ایمپرینت شده PN33 در کاهش عوارض عصبی شناختی ناشی از افزایش فنیل آلانین در مدل موش فنیل کتونوری (منصور تراب)	۲۶
استاد راهنما	دکتر پروانه رحیمی مقدم	گروه فارماکولوژی		پزشکی		تهیه و بررسی زخمپوش سلولزی برای پیوند گرافت پوستی در جراحی های ترمیمی و پلاستیک زخم سوختگی موش صحرایی (کیمیا دیده ور)	۲۷
استاد راهنما	دکتر پروانه رحیمی مقدم	گروه فارماکولوژی		پزشکی		بررسی ارتباط پلی مرفیسزم T/G۴۵ژن آدیپونکتین و چاقی در جمعیت ایرانی ساکن آمل (طهورا طهماسبی چاللو)	۲۸